Molecular-pathological prognostic factors of gastric cancer: a review

Invasion and metastasis are critical determinants of cancer morbidity. Genes and molecules participating in these steps must be regarded as potential prognostic factors. Growth factors and their receptors, cell-cycle regulators, cell-adhesion molecules and matrix-degrading enzymes are those to be used as prognostic factors, including epidermal growth factor (EGF), EGF receptor, K-sam, HER-2, interleukin (IL)-8, vascular endothelial growth factor (VEGF), cyclin E, p27, E-cadherin, CD44v6, matrix metalloproteinase-1 (MMP-1), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1). Alterations in epigenetics, such as aberrant DNA methylation and histone modification that are, in part, associated with the tumor progression of gastric cancer, can be candidate prognostic factors. The number of methylated genes may serve as a marker of tumor progression. Genetic polymorphism not only affects cancer susceptibility but also influences malignant phenotype; examples include single-nucleotide polymorphism in the HER-2 and MMP-9 genes. Comprehensive gene expression analyses are useful to search for novel genes related to invasion and metastasis and potential prognostic factors. Serial analysis of gene expression (SAGE) has identified several these genes, such as CDH17, APOE, FUS, COL1A1, COL1A2, GW112, and MIA. Overexpression of MIA is found to be associated with poor prognosis. Microarray analysis has great potential for identifying the characteristics of individual cancers, from the view point of gene expression profiles. A combination of these examinations can not only foretell a patient’s prognosis but can also give information directly connected with personalized cancer medicine and prevention.

[1]  H. Yokozaki,et al.  Genetic and epigenetic changes in stomach cancer. , 2001, International review of cytology.

[2]  H. Bidd,et al.  Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. , 2003, Human pathology.

[3]  H. Yokozaki,et al.  Molecular–pathological diagnosis of gastrointestinal tissues and its contribution to cancer histopathology , 1999, Pathology international.

[4]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[5]  J. Yokota,et al.  Genetic pathways to human cancer , 2003 .

[6]  C. Moskaluk,et al.  Gastric cancers overexpress S100A calcium-binding proteins. , 2002, Cancer research.

[7]  H. Yokozaki,et al.  Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma , 2001, International journal of cancer.

[8]  N. Oue,et al.  A single nucleotide polymorphism in the transmembrane domain coding region of HER‐2 is associated with development and malignant phenotype of gastric cancer , 2003, International journal of cancer.

[9]  Kazuhiro Yoshida,et al.  Frequent epigenetic inactivation of RIZ1 by promoter hypermethylation in human gastric carcinoma , 2004, International journal of cancer.

[10]  C. Caldas,et al.  CDH1 c‐160a promotor polymorphism is not associated with risk of stomach cancer , 2002, International journal of cancer.

[11]  A. Bosserhoff,et al.  Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. , 1994, Cancer research.

[12]  Y. Chung,et al.  Prognostic implications of microsatellite genotypes in gastric carcinoma , 2000, International journal of cancer.

[13]  Hiroki Kuniyasu,et al.  Molecular diagnosis of gastric cancer: present and future , 2001, Gastric Cancer.

[14]  K. Mimori,et al.  Prognostic score of gastric cancer determined by cDNA microarray. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  K. Hirata,et al.  Mucin phenotype and microsatellite instability in early multiple gastric cancers , 2002, International journal of cancer.

[16]  J. Vass,et al.  Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach , 2003, Oncogene.

[17]  C. Figdor,et al.  De-novo expression of CD44 and survival in gastric cancer , 1993, The Lancet.

[18]  E. Tahara.  Molecular mechanism of stomach carcinogenesis , 2005, Journal of Cancer Research and Clinical Oncology.

[19]  Kazuhiro Yoshida,et al.  Epigenetic inactivation of SOCS‐1 by CpG island hypermethylation in human gastric carcinoma , 2004, International journal of cancer.

[20]  S. Baylin,et al.  Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. , 1999, Cancer research.

[21]  H. Höfler,et al.  Gastric adenocarcinoma: pathomorphology and molecular pathology , 2001, Journal of Cancer Research and Clinical Oncology.

[22]  Kazuhiro Yoshida,et al.  Expression of POT1 is Associated with Tumor Stage and Telomere Length in Gastric Carcinoma , 2004, Cancer Research.

[23]  S. Leung,et al.  Soluble E-cadherin is a valid prognostic marker in gastric carcinoma , 2001, Gut.

[24]  G. Hommel,et al.  Prognostic value and clinicopathological profile of microsatellite instability in gastric cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  D. Pinkel,et al.  Genomic Alterations in Primary Gastric Adenocarcinomas Correlate with Clinicopathological Characteristics and Survival , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[26]  S. Hirohashi,et al.  Clinical Significance of Dysadherin Expression in Gastric Cancer Patients , 2004, Clinical Cancer Research.

[27]  Shuichi Tsutsumi,et al.  Global gene expression analysis of gastric cancer by oligonucleotide microarrays. , 2002, Cancer research.

[28]  M. Mori,et al.  Microsatellite instability in multiple gastric cancers , 1995, International journal of cancer.

[29]  R. Seruca,et al.  Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. , 1996, Gastroenterology.

[30]  Kazuhiro Yoshida,et al.  Frequent Loss of RUNX3 Expression by Promoter Hypermethylation in Gastric Carcinoma , 2004, Pathobiology.

[31]  K. Chayama,et al.  Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas? , 2001, European journal of cancer.

[32]  H. Yokozaki,et al.  Correlation of a single nucleotide polymorphism in the E-cadherin gene promoter with tumorigenesis and progression of gastric carcinoma in Japan. , 2003, International journal of oncology.

[33]  C. Fondevila,et al.  p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer , 2004, British Journal of Cancer.

[34]  T. Inoue,et al.  Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. , 1999, International journal of molecular medicine.

[35]  A. Bosserhoff,et al.  Functional role of MIA in melanocytes and early development of melanoma , 2004, Oncogene.

[36]  Yusuke Nakamura,et al.  Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. , 2002, Cancer research.

[37]  I. Fidler,et al.  Expression of interleukin-8 correlates with vascularity in human gastric carcinomas. , 1998, The American journal of pathology.

[38]  Kazuhiro Yoshida,et al.  A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[39]  Chien-Jen Chen,et al.  Association of the −160 C → a promoter polymorphism of E‐cadherin gene with gastric carcinoma risk , 2002, Cancer.

[40]  Ji-yeon Lee,et al.  Analysis of gene expression profiles of gastric normal and cancer tissues by SAGE. , 2003, Genomics.

[41]  N. Tomita,et al.  Expression of Tumor Suppressor Gene p16INK4 Products in Primary Gastric Cancer , 2000, Oncology.

[42]  Y. Mitani,et al.  Histone Acetylation and Gastrointestinal Carcinogenesis , 2003, Annals of the New York Academy of Sciences.

[43]  Kazuhiro Yoshida,et al.  A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer , 2004, Journal of Cancer Research and Clinical Oncology.

[44]  J. Fujimoto,et al.  Immunohistochemical Detection of Human Telomerase Reverse Transcriptase in Normal Mucosa and Precancerous Lesions of the Stomach , 1999, Japanese journal of cancer research : Gann.

[45]  H. Yokozaki,et al.  Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR‐beta in intestinal, diffuse–adherent, and diffuse–scattered type gastric carcinomas , 2002, The Journal of pathology.

[46]  L. David,et al.  Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma , 2004, Histopathology.

[47]  K. Hioki,et al.  Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer , 1998, International journal of cancer.

[48]  Kazuhiro Yoshida,et al.  A Single Nucleotide Polymorphism in the 5′ Untranslated Region of the EGF Gene Is Associated with Occurrence and Malignant Progression of Gastric Cancer , 2005, Pathobiology.

[49]  Y. Mitani,et al.  Gene Expression Profile of Gastric Carcinoma , 2004, Cancer Research.

[50]  I. Fidler.  Critical Determinants of Human Colon Cancer Metastasis , 1997 .

[51]  N. Oue,et al.  Reduced Expression of the TSP1 Gene and Its Association with Promoter Hypermethylation in Gastric Carcinoma , 2003, Oncology.

[52]  K. Naka,et al.  Effect of trichostatin A on cell growth and expression of cell cycle‐ and apoptosis‐related molecules in human gastric and oral carcinoma cell lines , 2000, International journal of cancer.

[53]  R. Hamelin,et al.  Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF‐β type II receptor, IGFII receptor, and BAX genes , 1999, The Journal of pathology.

[54]  S. Tsujitani,et al.  Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma , 1998, Cancer.

[55]  Ji Huang,et al.  [Serial analysis of gene expression]. , 2002, Yi chuan = Hereditas.

[56]  L. Ellis,et al.  Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  三谷 佳嗣.  Histone H3 acetylation is associated with reduced p21WAF1/CIP1 expression by gastric carcinoma , 2006 .

[58]  K. Mimori,et al.  Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. , 1997, British Journal of Cancer.

[59]  L. Ellis,et al.  Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  Hirofumi Nakayama,et al.  Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications , 2004, Cancer science.

[61]  Y. Okada,et al.  Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis , 1998, International journal of cancer.

[62]  Kazuhiro Yoshida,et al.  DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma , 2003, Cancer science.

[63]  G. Capellá,et al.  Genetic susceptibility and gastric cancer risk , 2002, International journal of cancer.

[64]  K. Mimori,et al.  Analysis of MT1‐MMP and MMP2 expression in human gastric cancers , 1997, International journal of cancer.

[65]  S. Natsugoe,et al.  The cooperative role of p27 with cyclin E in the prognosis of advanced gastric carcinoma , 2000, Cancer.

[66]  W. Stolz,et al.  Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. , 1997, Cancer research.

[67]  Y. Nakamura,et al.  Frequent replication errors at microsatellite loci in tumors of patients with multiple primary cancers. , 1994, Cancer Research.